Enter multiple symbols separated by commas



  • Behind the overnight slump in US biotech plays   Tuesday, 23 Dec 2014 | 10:24 PM ET
    Behind the overnight slump in US biotech plays

    Brewing price sensitivity in the sector, compounded with expensive valuations, led to the selloff in U.S. biotech stocks, says Peter Boockvar, Chief Market Analyst at The Lindsey Group.

  • Express Scripts' move weighs US biotech plays: Pro   Tuesday, 23 Dec 2014 | 6:43 PM ET
    Behind the overnight slump in US biotech names

    Express Scripts' decision to drop Gilead's Sovaldi treatment sparked fears that pharmaceutical firms may have to bow to pricing pressure moving forward, says Andrew McDonald, Co-Portfolio Manager at BioShares Funds.

  • Tracking biotech pullback   Tuesday, 23 Dec 2014 | 4:20 PM ET
    Tracking biotech pullback

    CNBC's Bob Pisani is tracking the action in biotech stocks into the end of the year. CNBC's Bertha Coombs, provides perspective.

  • Inside AbbVie's exclusive deal   Monday, 22 Dec 2014 | 1:58 PM ET
    Inside AbbVie's exclusive deal

    After Express Scripts exclusively selected AbbVie over Gilead and JNJ for its hepatitis C drug, CNBC's Meg Tirrell discusses how the news has impacted the entire biotech industry.

  • Lottery ticket sector of 2015   Monday, 22 Dec 2014 | 12:46 PM ET
    Lottery ticket sector of 2015

    Mark Fisher, MBF Clearing Corp. chairman, shares his favorite stock in the biotech space.

  • Express Scripts selects AbbVie over Gilead   Monday, 22 Dec 2014 | 9:16 AM ET
    Express Scripts selects AbbVie over Gilead

    CNBC's Jim Cramer and David Faber discuss Express Scripts' selection of AbbVie over Gilead for its hepatitis C drug and what this means for Gilead.

  • Juno CEO: Developing new hope for cancer   Friday, 19 Dec 2014 | 10:43 AM ET
    Juno CEO: Developing new hope for cancer

    "We're trying to develop treatments that offer new hope or patients battling cancer," says Hans Bishop, Juno Therapeutics CEO, explaining the technology behind Juno.

  • Isis Pharmaceuticals' game-changer drug   Thursday, 18 Dec 2014 | 6:25 PM ET
    Isis Pharmaceuticals' game-changer drug

    Because of its anti-coagulant drug, FXI, Mad Money's Jim Cramer thinks Isis Pharmaceuticals can climb much higher.

  • *Decision marks win for International Stem Cell Corp. BRUSSELS/ LONDON, Dec 18- Europe's top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented. Thursday's judgment by the European Court of Justice was made following a case...

  • Celgene CEO: Cancer drug pipeline booming   Monday, 8 Dec 2014 | 12:37 PM ET
    Celgene CEO: Cancer drug pipeline booming

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about exciting new drugs emerging from Celgene's pipeline and the progress being made with Multiple myeloma.

  • Two biotechs to track now   Friday, 5 Dec 2014 | 5:23 PM ET
    Two biotechs to track now

    Two stocks you need to watch ahead of San Francisco's 56th ASH hematology conference, with CNBC's Meg Tirrell.

  • RBC's biotech picks: CELG, BMRN & VRTX   Tuesday, 2 Dec 2014 | 5:18 PM ET
    RBC's biotech picks: CELG, BMRN & VRTX

    Discussing some of the best stocks in the biotech industry going into 2015, with Michael Yee, RBC Capital Markets.

  • Biogen shows its hand   Tuesday, 2 Dec 2014 | 5:15 PM ET
    Biogen shows its hand

    CNBC's Meg Tirrell provides insight to Biogen Idec's promising early study on its experimental medicine for Alzheimer's disease. Michael Yee, RBC Capital Markets, explains why the stock is headed higher from here.

  • Biogen's fight against Alzheimer's   Tuesday, 2 Dec 2014 | 2:19 PM ET
    Biogen's fight against Alzheimer's

    Biogen's Alzheimer's drug has shown promise in studies, with CNBC's Meg Tirrell.

  • Banned in US, cleared in the UK   Monday, 1 Dec 2014 | 7:00 PM ET
    Banned in US, DNA testing service reaches UK

    A Google-backed service to map DNA and identify potential risk factors for some diseases has been launched in the U.K., months after it was banned in the U.S..

  • Tracking the Allergan-Actavis merger   Monday, 17 Nov 2014 | 7:32 PM ET
    Tracking the Allergan-Actavis merger

    Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.

  • Dendreon files bankruptcy protection   Monday, 10 Nov 2014 | 10:38 AM ET
    Dendreon files bankruptcy protection

    Prostate cancer drug developer Dendreon has filed for Chapter 11 bankruptcy protection. CNBC's Meg Tirrell takes a close look at what contributed to the company's downfall.

  • Integrating vets into corporate America: J&J CEO   Wednesday, 5 Nov 2014 | 2:30 PM ET
    Integrating vets into corporate America: J&J CEO

    CNBC's Meg Tirrell speaks to Alex Gorsky, Johnson & Johnson chairman & CEO, about helping military veterans transition from the battlefield into corporate America.

  • Arena Pharma's 'Belviq' potential   Monday, 3 Nov 2014 | 2:40 PM ET
    Arena Pharma's 'Belviq' potential

    Jack Lief, Arena Pharmaceutical president & CEO, breaks down the company's Q3 earnings and discusses the outlook for its weight loss drug "Belviq."

  • Russia comes to Silicon Valley to recruit Monday, 3 Nov 2014 | 10:52 AM ET
    The Skolkovo Hypercube  in Moscow, Russia.

    Russia has a new tech city chock-full of co-working spaces, seed funding, and a research university. All they need now are the technologists.